Literature Selection / Selezione della Letteratura

• Bilimoria KY et al.: "Evaluating the impact of preoperative breast magnetic resonance imaging on the surgical management of newly diagnosed breast cancers", Arch Surg. 2007 May;142(5):441-7
• de Azambuja E et al.: "Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12 155 patients", Br J Cancer. 2007 May 21;96(10):1504-1513
• Chapman C et al.: "Autoantibodies in breast cancer: their use as an aid to early diagnosis", Ann Oncol. 2007 May;18(5):868-73
• Van Goethem M et al.: "MR mammography is useful in the preoperative locoregional staging of breast carcinomas with extensive intraductal component", Eur J Radiol. 2007 May;62(2):273-82
• Montgomery DA et al.: "Alternative methods of follow up in breast cancer: a systematic review of the literature", Br J Cancer. 2007 May 8; [Epub ahead of print]
• Apostolaki S et al.: "Circulating HER2 mRNA-positive cells in the peripheral blood of patients with stage I and II breast cancer after the administration of adjuvant chemotherapy: evaluation of their clinical relevance", Ann Oncol. 2007 May;18(5):851-8
• Doyle JJ et al.: "Radiation therapy, cardiac risk factors, and cardiac toxicity in early-stage breast cancer patients", Int J Radiat Oncol Biol Phys. 2007 May 1;68(1):82-93
• Savarese TM et al.: "Correlation of umbilical cord blood hormones and growth factors with stem cell potential: implications for the prenatal origin of breast cancer hypothesis", Breast Cancer Res. 2007 May 14;9(3):R29 [Epub ahead of print]
• Millar JA et al.: "Cost effectiveness of trastuzumab in the adjuvant treatment of early breast cancer: a lifetime model", Pharmacoeconomics. 2007;25(5):429-42
• van der Leest M et al.: "The safety of breast-conserving therapy in patients with breast cancer aged < or = 40 years", Cancer. 2007 May 15;109(10):1957-64
• Laki F et al.: "Prophylactic salpingo-oophorectomy in a series of 89 women carrying a BRCA1 or a BRCA2 mutation”, Cancer. 2007 May 1;109(9):1784-90
• Daley AJ et al.: "Randomized trial of exercise therapy in women treated for breast cancer", J Clin Oncol. 2007 May 1;25(13):1713-21

Editorial / Editoriale

• "The value of fiberoptic ductoscopy combined with cytology testing as a diagnostic procedure in women with nipple discharge"  - Guangyu Liu, Department of Breast Surgery, Cancer Hospital/Cancer Institute, Fudan University, Shanghai, People's Republic of China
  
  "Fiberoptic ductoscopy system has been introduced as a diagnosing method for nipple discharge since the 1990s. As indicated by histological findings, the FDS results could be categorized into three major groups: 1) non-neoplastic changes, 2) papillary lesions, and 3) malignant-like lesions. FDS was much more reliable than mammography and sonography in diagnosis of non-palpable breast cancer associated with nipple discharge. Cytology testing is a good method to be used in conjunction with FDS. Microdochectomy is still a standard and definite diagnostic procedure for intraductal lesions found by FDS. However, FDS-guided endoscopic biopsy is promising to avoid erroneous sampling, especially for benign papillomas".
  (Comment on paper: Liu GY et al.: "Fiberoptic ductoscopy combined with cytology testing in the patients of spontaneous nipple discharge", Breast Cancer Res Treat. 2007 May 2; [Epub ahead of print])

News from Healthcare Companies / Notizie dalle Aziende

• "Herceptin approved in Europe for use in combination with an aromatase inhibitor for the treatment of patients with HER2 and hormone receptor-co-positive metastatic breast cancer" - Roche

Video and Lectures / Conferenze e Video (link)

• "Too Young for Breast Cancer?" - The University of Texas, M. D. Anderson Cancer Center, Houston, TX, USA  - www.mdanderson.org

Calendar of Events / Prossimi Eventi Senologici

• 14th UICC Reach to Recovery International Breast Cancer Support Conference, May 30 - Jun 2, 2007, Stockholm, Sweden
• 43rd ASCO Annual Meeting,  1-5 Jun 2007, Chicago, USA
• VII Madrid Breast Cancer Conference, 20-22 Jun 2007, Madrid, Spain
• 9th Milan Breast Cancer Conference, 20-22 Jun 2007, Milan, Italy

Literature Selection / Selezione della Letteratura

• Edgren G et al.;"Risk of cancer after blood transfusion from donors with subclinical cancer: a retrospective cohort study", Lancet. 2007 May 19;369(9574):1724-30
• Coyne JC et al.: "Psychotherapy and survival in cancer: the conflict between hope and evidence", Psychol Bull. 2007 May;133(3):367-94
• Ryerson AB et al.: "Symptoms, Diagnoses, and Time to Key Diagnostic Procedures Among Older U.S. Women With Ovarian Cancer", Obstet Gynecol. 2007 May;109(5):1053-1061
• Van Nagell JR et al.: “Ovarian cancer screening with annual transvaginal sonography: findings of 25,000 women screened”, Cancer. 2007 May 1;109(9):1887-96
• Morgan DJ et al.: "Is laparoscopically assisted radical vaginal hysterectomy for cervical carcinoma safe? A case control study with follow up", BJOG. 2007 May;114(5):537-42.
• Joura EA et al.: "Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials", Lancet. 2007 May 19;369(9574):1693-702
• D'Souza G et al.: "Case-control study of human papillomavirus and oropharyngeal cancer", N Engl J Med 2007 May; 356:1944-1956
• Flossmann E et al.: "Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies", Lancet. 2007 May 12;369(9573):1603-13
• Chan AT et al.: “Aspirin and the risk of colorectal cancer in relation to the expression of COX-2”, N Engl J Med. 2007 May 24;356(21):2131-42
• Rees JR et al.: "Tea consumption and basal cell and squamous cell skin cancer: results of a case-control study", J Am Acad Dermatol. 2007 May; 56(5):781-5
• Khurana V et al.: "Statins Reduce the Risk of Lung Cancer in Humans: A Large Case-Control Study of US Veterans", Chest 2007 May; 131:1282-1288
• Lee JE et al.: "Alcohol intake and renal cell cancer in a pooled analysis of 12 prospective studies", J Natl Cancer Inst. 2007 May 16;99(10):801-10

Editorial / Editoriale

• "Relation between the age at treatment for undescended testis and the risk of testicular cancer" - Andreas Pettersson,  Clinical Epidemiology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden

"In our cohort study of 16,983 men who were surgically treated for cryptorchidism, we found that the risk of testicular cancer among men who were treated at 13 years of age or older was approximately twice that among men who underwent orchiopexy before the age of 13. The results indicate that age at treatment for cryptorchidism has an effect on the risk of testicular cancer, and thus that cryptorchidism in itself could be a cause of testicular cancer. Current clinical guidelines recommend treatment for cryptorchidism before 2 years of age, or as early as 6 months of age. Thus, our results support these guidelines. Whether treatment as early as before 1 year of age decreases the risk of future testicular cancer even further is not known, and needs to be studied further. The results also suggest that puberty, defined arbitrarily in our study as beginning at the age of 13 years, is another crucial event in testicular carcinogenesis. Testicular cancer is generally believed to be caused by environmental factors operating already in utero. Based on the results of this and other studies, we propose that future studies on the aetiology of testicular should also take postnatal exposures during puberty into account." .
(Comment on paper: Pettersson A et al.: "Age at surgery for undescended testis and risk of testicular cancer.", N Engl J Med. 2007 May 3;356(18):1835-41)

Press Releases / Comunicati Stampa

• "Risk of Lymphoma Increases with Hepatitis C Virus Infection" - National Institutes of Health (NIH), U. S. Department of Health and Human Services
• "Lymphocyte Count Found to be a Predictor of Survival for Young Patients with Leukemia" - The University of Texas, M. D. Anderson Cancer Center, Houston, TX, USA
• "Sunscreen and Summer Sun Safety" - The University of Texas, M. D. Anderson Cancer Center, Houston, TX, USA
• "Diabetes drug dramatically boosts power of platinum chemotherapy" - Dana-Farber Cancer Institute, Boston, MA, USA

Clinical Guidelines / Linee guida cliniche (link)

• "Microwave ablation for the treatment of metastases in the liver: Guidance" - NICE - National Institute For Clinical Excellence, London, UK - www.nice.org.uk

Video and Lectures / Conferenze e Video (link)

• "Focus On Lymphedema - Balancing Precautions and Exercise" - Memorial Sloan-Kettering Cancer Center, New York, USA  - www.mskcc.org

Literature Selection / Selezione della Letteratura

• Garland SM et al.: "Quadrivalent vaccine against the human papillovmavirus to prevent anogenital diseases", N Engl J Med 2007 May; 356:1928-1943 - Un vaccino quadrivalente contro i tipi 6, 11, 16 e 18 del Papillomavirus umano è in grado di ridurre l'incidenza di lesioni esterne anogenitali (condilomi e lesioni precancerose) in giovani donne
• Middleton ET et al.: "The effects of short-term hormone replacement therapy on long-term bone mineral density", Climacteric. 2007 Jun;10(3):257-63 - In donne che si sottopongono ad una terapia ormonale sostitutiva di breve durata  (2-4 anni) nelle fasi precoci della menopausa, gli effetti positivi sulla densità minerale ossea sono evidenti anche a lungo termine

Editorial / Editoriale

• "Quadrivalent vaccine against HPV and prevention of anogenital diseases" - Suzanne Garland, Microbiology and Infectious Diseases Department, Royal Women's Hospital, and the University of Melbourne, Melbourne, Australia

"Key points on our paper are the following: 1) In young women not previously infected with HPV 6,11, 16 or 18 the quadrivalent vaccine is 100% efficacious in preventing infection and associated cervical dysplasia from these vaccine related HPV types. The prevention of  the precancerous lesions of CIN 2/3 are thus surrogates for prevention of cervical cancer . 2) In young women not previously infected with HPV 6,11, 16 or 18 the quadrivalent vaccine is 100% efficacious in preventing infection and associated vaginal and or vulvar intraepithelial neoplasias grade 2/3, surrogate markers for vaginal and vulval cancers. 3) In young women not previously infected with HPV 6,11, 16 or 18 the quadrivalent vaccine is 100% efficacious in preventing infection and associated external anogenital warts 4) In young women not previously infected with HPV 6,11, 16 or 18 the quadrivalent vaccine is 100% efficacious in preventing infection and associated adenocarcinoma in situ grade 2/3,  the precancerous lesions of adenocarcinoma, a cancer poorly predicted by Pap screening cytology. 5)  In young women previously infected with any of HPV 6,11, 16 or 18 the quadrivalent vaccine is 100% efficacious in preventing infection and associated disease from those vaccine related HPV types to which they have not been previously infected. I.e. a woman may had previous types six, but with the vaccine is equally protected to 16, 18 and 11 and as compared to a woman completely naïve to all four viruses". 
(Comment on paper: Garland SM et al.: "Quadrivalent vaccine against the human papillovmavirus to prevent anogenital diseases", N Engl J Med 2007 May; 356:1928-1943)